Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR

Published:2020-08 Issue:8 Volume:20 Page:509-518
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Mateos Maria-Victoria,Sonneveld Pieter,Hungria Vania,Nooka Ajay K.,Estell Jane A.,Barreto Wolney,Corradini Paolo,Min Chang-Ki,Medvedova Eva,Weisel Katja,Chiu Christopher,Schecter Jordan M.,Amin Himal,Qin Xiang,Ukropec Jon,Kobos Rachel,Spencer Andrew

Funder

Amgen

Celgene

Janssen

Karyopharm

Bristol-Myers Squibb

Sanofi

Janssen-Cilag

Takeda

Janssen Research & Development

Janssen Global Services

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference33 articles.

1. Current treatment landscape for relapsed and/or refractory multiple myeloma;Dimopoulos;Nat Rev Clin Oncol,2015

2. Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma;Korde;JAMA Oncol,2015

3. Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide;Moreau;Blood Cancer J,2019

4. Clinical use of proteasome inhibitors in the treatment of multiple myeloma;Merin;Pharmaceuticals (Basel),2015

5. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study;Dimopoulos;Lancet Oncol,2016

Cited by 106 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of daratumumab on multiple myeloma patients with renal insufficiency: a systematic review and meta-analysis;Hematology;2024-09-09

2. Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial;The Lancet Haematology;2024-09

3. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma;New England Journal of Medicine;2024-08

4. Prognosis of concurrent renal impairment at diagnosis of multiple myeloma: a systematic review;Annals of Medicine;2024-07-22

5. Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real‐world evidence;British Journal of Haematology;2024-07-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3